Skip to main content


Table 6 Short-term efficacy of monotherapy combined with anti-angiogenic agents after PD with monotherapy

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Short-term efficacyNumber of patients (Percent)
Complete response (CR)0 (0)
Partial response (PR)0 (0)
Stable disease (SD)2 (66.7)
Progressive disease (PD)1 (33.3)